Slynd (drospirenone) is now covered by the Régie de l’assurance maladie du Québec

12 July 2023 - Duchesnay is pleased to announce that Slynd (drospirenone 4 mg), used to prevent pregnancy in girls ...

Read more →

AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec

17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...

Read more →

Valeo Pharma obtains public reimbursement for Onstryv in Quebec

7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...

Read more →

Medexus secures public reimbursement for Cuvposa in Quebec

1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...

Read more →

AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss

17 October 2022 - Quebec leads the way as the first province to reimburse Luxturna (voretigene neparvovec) for previously untreatable inherited ...

Read more →

HLS Therapeutics obtains public reimbursement for Vascepa in Quebec

24 May 2022 - Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with ...

Read more →

Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...

Read more →

Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults

2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...

Read more →

AbbVie announces first provincial reimbursements for Venclexta (venetoclax) in combination with azacitidine for acute myeloid leukaemia patients

10 February 2022 - Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance, Quebec, Saskatchewan, and ...

Read more →

Quebec to impose health tax on unvaccinated Canadians

12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia

15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...

Read more →

Novartis applauds Quebec, the first province to list Zolgensma for the treatment of paediatric patients with spinal muscular atrophy

15 October 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec, effective October 20th will apply for children ...

Read more →

Quebec extends public reimbursement of Dupixent (dupilumab) for the treatment of moderate to severe atopic dermatitis to include adolescents

1 June 2021 - Public reimbursement under the Régie de l'assurance maladie du Québec will now apply for Canadians aged ...

Read more →

Quebec announces intention to implement a biosimilar switching policy

18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...

Read more →